BiotechTube

Carbetocin

Phase 3Recruiting
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperphagia in Prader-Willi Syndrome

Conditions

Hyperphagia in Prader-Willi Syndrome

Trial Timeline

Mar 11, 2024 → Jun 1, 2029

NCT ID
NCT06420297

About Carbetocin

Carbetocin is a phase 3 stage product being developed by Acadia Pharmaceuticals for Hyperphagia in Prader-Willi Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06420297. Target conditions include Hyperphagia in Prader-Willi Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06420297Phase 3Recruiting

Competing Products

3 competing products in Hyperphagia in Prader-Willi Syndrome

See all competitors
ProductCompanyStageHype Score
Carbetocin + PlaceboAcadia PharmaceuticalsPhase 3
72
Placebo + ARD-101Aardvark TherapeuticsPhase 3
69
ARD-101Aardvark TherapeuticsPhase 3
69

Other Products from Acadia Pharmaceuticals

PimavanserinApproved
80
PimavanserinApproved
80
PimavanserinApproved
80
PimavanserinPhase 3
72
Pimavanserin tartrate (ACP-103) + Pimavanserin tartrate (ACP-103) + PlaceboPhase 3
72